SGYP/Pharm - I'm sold, but not on the time-frame.
Based on its ongoing dialogue with the FDA and the achievement of its mid-cycle review milestone, Synergy Pharmaceuticals (NASDAQ:SGYP) maintains its optimism that lead product candidate plecanatide will be approved to treat chronic ideopathic constipation (CIC) by its January 29, 2017 PDUFA date.
In addition, it will continue patient enrollment in its two current Phase 3 clinical trials assessing plecanatide in irritable bowel syndrome with constipation (IBS-C). The decision was made after trial monitoring showed a slower enrollment pace and an increase in the number of patients not meeting randomization criteria after the screening period prior to starting treatment.
Pharmboy July 15th, 2016 at 10:02 am | (Unlocked) | Permalink
SGYP – so, for those new or missed my previous posts about this company, look at IRWD stock price. Look now at SGYP. SGYP has a better drug than IRWD, but IRWD's drug is on the market. SGYP has stellar data, so I have the stock, and the Oct 6 C and Ps sold. I can roll the puts, which are ITM (and I am up on them, but down overall b'c of an original roll.)A new play on SGYP is the Jan17 4/5 BCS with the sale of the 2.5 P for a net 10c credit. Net profit is $55/contract. One can also buy the stock and sell the Jan $5 Cs for 50c and 2.5P for another 40c to goose the profits. I like the stock with the calls for small accounts. A few hundred shares is a good way to go. Either way, I like the company's chances …..
I assume, if they do get approved, that it's a long-term benefit. Obviously, that trade is a huge winner already, so thanks for that one.
